Loading
Cardiac Valve Diseases and Treatments · Journal article
Complex Issues of Cardiovascular Diseases · June 29, 2026
A consensus or society position rather than new primary data.
This is a narrative synthesis of the evolution of coronary stent technology from bare-metal stents through drug-eluting and bioresorbable designs to current anti-inflammatory variants, based on a literature review of RCTs and meta-analyses published 1994–2025. It describes historical trends and emerging directions rather than reporting a novel trial result, and should be read as a state-of-the-art overview rather than evidence for a specific intervention.
Analytical literature review. Literature addressing coronary stent technology development, design, materials, and clinical performance across multiple generations. Intervention: Evolution and comparison of coronary stent technologies (bare-metal, drug-eluting, bioresorbable, anti-inflammatory designs). Compared with: Multiple comparators across historical stent generations (balloon angioplasty, bare-metal vs drug-eluting, bioresorbable vs conventional, etc.).
Coronary stent implantation reduced thrombosis and repeat revascularization compared to balloon angioplasty Drug-eluting stents in the 2000s decreased neointimal hyperplasia and repeat interventions but introduced late thrombosis risk Bioresorbable stents failed to show superiority in large randomized trials
Modern stents show improved efficacy and safety; novel anti-inflammatory agents (colchicine) are under development
Clinicians should understand the historical trajectory of stent design and the trade-offs (efficacy vs thrombosis risk, durability vs biocompatibility) that guide current device selection. This review offers context for why newer anti-inflammatory and biocompatible designs are being pursued, but does not provide direct comparative outcome data to change current practice.
A systematic literature review synthesizing the evolution of coronary stent technology and design from major RCTs and meta-analyses, offering narrative synthesis of technological progress rather than a novel empirical finding.
As stated by the source record.
Clinicians should understand the historical trajectory of stent design and the trade-offs (efficacy vs thrombosis risk, durability vs biocompatibility) that guide current device selection. This review offers context for why newer anti-inflammatory and biocompatible designs are being pursued, but does not provide direct comparative outcome data to change current practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Highlights This review presents a systematic overview of scientific achievements in the development and use of coronary stents. It includes an analysis of key studies addressing various aspects of their performance. The article examines existing generations of coronary stents, materials used in their manufacture, design features, and also describes the latest advancements in this field. Abstract To trace the evolution of coronary stents and identify promising directions in the development of endovascular surgery.An analytical literature review was conducted, including results from major randomized clinical trials and meta-analyses published in leading cardiology journals between 1994 and 2025.The introduction of coronary stent implantation technology reduced the incidence of thrombosis and the need for repeat revascularization compared to balloon angioplasty. However, a high risk of restenosis limited their use. The emergence of drug-eluting stents in the 2000s led to a sharp decrease in neointimal hyperplasia and repeat interventions but was associated with a risk of late thrombosis. Modern generations of stents demonstrate improved efficacy and safety. Bioresorbable stents were an innovative development but failed to show superiority in large randomized trials. Currently, stents incorporating novel anti-inflammatory agents (such as colchicine) are under development. The evolution of coronary stents reflects the pursuit of an optimal biocompatible device that induces minimal inflammatory response, promotes rapid vascular wall healing, and eliminates the need for prolonged dual antiplatelet therapy. A literature search was conducted in the PubMed electronic database for publications from 1994 to 2025. The following keywords were used: «coronary stent», «bare metal stent», «drug-eluting stent», «polymer-free», and «bioresorbable scaffold». The review included clinical studies, systematic reviews, meta-analyses, randomized controlled trials, and comparative studies relevant to the topic of analysis.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.